Advances in the Therapy of t(8;21) Acute Myeloid Leukemia.
10.7534/j.issn.1009-2137.2015.02.055
- Author:
Dan-Dan LI
1
;
Li-Ping DOU
1
;
Yong-Hui LI
1
;
Li YU
2
Author Information
1. Chinese PLA Medical College, Department of Hematology of Chinese PLA General Hospital, Beijing 100853, China.
2. Chinese PLA Medical College, Department of Hematology of Chinese PLA General Hospital, Beijing 100853, China. E-mail: chunhuiliyu@yahoo.com.
- Publication Type:Journal Article
- MeSH:
Chromosomes, Human, Pair 22;
Epigenesis, Genetic;
Humans;
Leukemia, Myeloid, Acute;
Translocation, Genetic
- From:
Journal of Experimental Hematology
2015;23(2):578-582
- CountryChina
- Language:Chinese
-
Abstract:
The t(8;21)(q22;q22) translocation is the most common chromosomal abnormalities in AML, and the chromosomal translocation forms AML1-ETO. The t(8;21) AML is a heterogeneity disease. It is unclear for how to treat the relapsed or refractory AML. Recently, the clinical trials and pathogenesis have made great progress. This article summarizes the current clinical trials and recruiting t(8;21) AML clinical trials and researches that related to treatment are as followed: epigenetics, JAK/STAT signaling, steroid, Chinese traditional medicine, and interferon. With the progress of pathogenesis researches, more and more treatments will translate into clinical trials, which can provide more optional choice for relapsed or refractory t(8;21) AML. In this article the AML1-ETO structure and t(8;21) AML pathogenesis, the clinical researches of t(8;21) AML treatment and basic researches of t(8;21) AML treatment are summarized.
